What Research Actually Shows About Cannabis and Tuberculosis
Tuberculosis (TB) remains a serious infectious disease caused by Mycobacterium tuberculosis, a bacterium that most often affects the lungs. It spreads through the air when a person with active pulmonary TB coughs, speaks or sings. TB is curable with appropriate antibiotics, but drug-resistant forms can require more complex treatment and may cause serious illness.
The evidence reviewed here does not show that medical cannabis cures TB or replaces standard treatment. Several studies cited in discussions of cannabis and TB involve laboratory experiments, animal models or traditional medicinal plants—not clinical trials showing that cannabis treats tuberculosis in people.
How tuberculosis is diagnosed and treated
People with active pulmonary TB may develop a cough lasting three weeks or longer, chest pain, fatigue, fever, night sweats, loss of appetite, weight loss or coughing up blood. TB can also affect organs outside the lungs, including the kidneys, brain and spine. By contrast, people with latent or inactive TB infection generally have no symptoms and do not spread the bacteria.
Diagnosis may involve a TB blood test or skin test, a chest X-ray, sputum testing and drug-susceptibility testing. Treatment depends on whether the infection is latent or active and whether the bacteria are drug-resistant. For drug-susceptible TB, commonly used medicines include rifampicin, isoniazid, pyrazinamide and ethambutol. Patients must take the prescribed combination for the full course; stopping early or taking medicines incorrectly can promote drug resistance. The World Health Organization’s current TB treatment guidelines provide evidence-based recommendations for drug-susceptible and drug-resistant disease.
What the cannabis-related studies found
One frequently cited claim is that a United Nations Office on Drugs and Crime study found cannabis resin capable of inhibiting TB bacteria. The identifiable UNODC World Drug Report is primarily a report on drug markets and patterns of use; it is not evidence from a clinical trial demonstrating that cannabis resin treats TB. No reliable clinical evidence establishes cannabis resin as an anti-TB medicine.
A 2016 laboratory study examined the cannabis-related compound β-caryophyllene, a cannabinoid receptor 2 (CB2) agonist, in an inflammatory model involving Mycobacterium bovis Bacillus Calmette–Guérin (BCG). The researchers reported that the compound reduced neutrophil migration and suggested that CB2 signaling might help regulate inflammation. The study, available through PubMed, did not test cannabis as a treatment for people with tuberculosis, did not establish bacterial clearance and did not show that the compound could replace antibiotics.
Another study often connected to TB examined traditional medicinal plants used by Bapedi healers in South Africa. The 2013 survey documented plants used for TB and reported that 71.4% had antimicrobial properties reported in earlier literature or similar traditional uses elsewhere. That finding describes ethnobotanical knowledge and supporting literature; it does not prove that the plants cure TB or that they are safe or effective when used in place of medical treatment. A separate laboratory investigation tested selected plant extracts for antimycobacterial activity, but laboratory activity is an early step in drug discovery rather than proof of clinical benefit.
Finally, a 2015 PLOS ONE study investigated chronic THC administration in obese and lean mice. THC reduced weight gain and altered certain gut-microbiota patterns in mice fed a high-fat diet. The authors explicitly noted that further work was needed to determine whether the microbiota changes caused the weight effects or resulted from them. The study was not a TB study and provides no evidence that THC kills M. tuberculosis or improves TB treatment.
Why caution is important
Cannabis compounds may eventually contribute to research on inflammation or the development of new medicines, but the current evidence does not support cannabis as a treatment for active or latent TB. Patients should not stop, shorten or alter their TB regimen because of cannabis use or claims about cannabinoids. Anyone with possible TB symptoms should seek medical evaluation promptly.
Smoking cannabis may be particularly inappropriate for someone with pulmonary disease. According to the Centers for Disease Control and Prevention’s information on cannabis and lung health, smoked cannabis can harm lung tissue and is associated with cough, bronchitis and increased mucus production. Any cannabis product may also interact with medicines or cause impairment, so patients should discuss its use with their clinician.
The most accurate conclusion is that cannabinoid and medicinal-plant research offers hypotheses for future investigation—not a proven cannabis-based therapy for tuberculosis. For now, timely diagnosis, appropriate antibiotics, adherence to the complete regimen and medical monitoring remain the foundation of TB care.
